Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Carducci

Showing results (301-310 of 386) with videos related to

Pageof 39
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2017
Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without DocetaxelLauren C Harshman, Yu-Hui Chen, Glenn Liu, et al.
Nature Medicine|April 14, 2009
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancerWennuan Liu, Sari Laitinen, Sofia Khan, et al.
The Prostate|May 28, 2015
A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determinationChanning J Paller, Michelle A Rudek, Xian C Zhou, et al.
Science Translational Medicine|June 30, 2012
Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapySamuel R Denmeade, Annastasiah M Mhaka, D Marc Rosen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2004
Factors affecting cytochrome P-450 3A activity in cancer patientsSharyn D Baker, Ron H N van Schaik, Laurent P Rivory, et al.
Epigenetics|July 25, 2013
Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitorsMadeleine S Q Kortenhorst, Michel D Wissing, Ronald Rodríguez, et al.
Cancer Medicine|July 4, 2014
Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancerChanning J Paller, Michel D Wissing, Janet Mendonca, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 25, 2025
Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trialA Tripathi, Y Chen, D F Jarrard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkersEmmanuel S Antonarakis, Elisabeth I Heath, Janet R Walczak, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 24, 2015
Comparison of Prostate-Specific Membrane Antigen-Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate CancerSteven P Rowe, Katarzyna J Macura, Anthony Ciarallo, et al.
Pageof 39

Showing results (301-310 of 386) with videos related to

Sort By:
Pageof 39
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2017
Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without DocetaxelLauren C Harshman, Yu-Hui Chen, Glenn Liu, et al.
Nature Medicine|April 14, 2009
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancerWennuan Liu, Sari Laitinen, Sofia Khan, et al.
The Prostate|May 28, 2015
A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determinationChanning J Paller, Michelle A Rudek, Xian C Zhou, et al.
Science Translational Medicine|June 30, 2012
Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapySamuel R Denmeade, Annastasiah M Mhaka, D Marc Rosen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2004
Factors affecting cytochrome P-450 3A activity in cancer patientsSharyn D Baker, Ron H N van Schaik, Laurent P Rivory, et al.
Epigenetics|July 25, 2013
Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitorsMadeleine S Q Kortenhorst, Michel D Wissing, Ronald Rodríguez, et al.
Cancer Medicine|July 4, 2014
Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancerChanning J Paller, Michel D Wissing, Janet Mendonca, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 25, 2025
Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trialA Tripathi, Y Chen, D F Jarrard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkersEmmanuel S Antonarakis, Elisabeth I Heath, Janet R Walczak, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 24, 2015
Comparison of Prostate-Specific Membrane Antigen-Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate CancerSteven P Rowe, Katarzyna J Macura, Anthony Ciarallo, et al.
Pageof 39